Molecular Testing
Despite progress, barriers to lung cancer biomarker testing persist
Acceptance and utilization of lung cancer biomarker testing has increased in the past 6 years, but key barriers persist, according to survey results.
VIDEO: Unmet needs in CML treatment
Healio spoke with Gwen Nichols, MD, about unmet needs in CML.
Initiating treatment after molecular testing may improve outcomes for advanced NSCLC
CHICAGO — Patients diagnosed with stage IV non-small cell lung cancer who received a tyrosine kinase inhibitor following clinical molecular testing had better OS, according to research presented at ASCO Annual Meeting.
Top in hem/onc: Molecular testing in lung cancer; gender disparities in NIH funding
Despite its benefits, data suggest that comprehensive molecular testing in patients with non-small cell lung cancer is underutilized due to a lack of resources.
Comprehensive molecular testing in lung cancer ‘absolutely crucial’ yet underutilized
Precision medicine has shown great potential to improve treatment outcomes and prolong survival of patients with lung cancer, as biomarker-driven therapies continue to extend their reach in this space.
VIDEO: Molecular tests may provide valuable prognostic information for thyroid cancer
In this video, John M. Skaugen, MD, an assistant professor of pathology at University of Pittsburgh discusses his study presented at the American Thyroid Association 2022 annual meeting.
High sensitivity observed for most molecular tests assessing malignancy of thyroid nodules
Studies analyzing four molecular tests commonly used to assess malignancy in thyroid nodules have high sensitivity despite several limitations, according to findings from a systematic review and meta-analysis.
Germline testing ‘should be considered’ for all patients with lung cancer, data suggest
About 15% of a large cohort of patients with lung cancer had pathogenic germline variants, nearly all of which could be clinically actionable, according to study results presented during an ASCO Plenary Series session.
NCI program to provide molecular characterization of childhood cancers
National Cancer Institute announced the launch of a program that offers molecular characterization of childhood cancers.
Risk stratification, molecular testing among recent advances in thyroid cancer treatment
During the past 2 decades, Endocrine Today has reported on the latest developments in treating thyroid cancer. For its 20th year, the publication is taking a look back.